We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Leukocyte Counts Influenced by Genetic Variants

By LabMedica International staff writers
Posted on 27 Jul 2011
White blood cell (WBC) levels are influenced by genetic variants at more than a dozen loci for different ethnic groups. More...


Large genome wide association studies (GWAS), found some genetic variants affecting total WBC counts and some influencing leukocyte subtypes such as lymphocytes, neutrophils, basophils, eosinophils, or monocytes.

Numerous international collaborators, in separate studies, supported by the US National Institutes of Health, Bethesda, MD, USA), examined the WBC counts in 14,792 Japanese, 16,388 African-Americans, and 19,509 white participants, as well as additional replication and comparison cohorts, looking for genetic variants. Benign neutropenia, defined as absolute neutrophil count of less than 1.56 × 109 cells/L on repeated occasions, is found in up to 40% of populations of African descent, and approximately 5% of those of African descent living in America, but less than 1% of white Americans of European descent.

The total WBC counts, and neutrophil counts in particular, are typically 10% to 20% lower in African-Americans than in whites. This difference has been attributed to a variant of the Duffy Antigen Receptor for Chemokines (DARC), common in Africa, which provides a selective advantage in malarial regions and influences production and migration of neutrophils. The authors suggest that characterizing the variants associated with WBC and neutrophil counts could help to inform clinical approaches to cancer-associated neutropenia or hematopoietic stem cell mobilization.

The Japanese study found nine GWAS-significant associations between genetic loci and WBC subtype counts and confirmed three loci already known to influence WBC counts. The study on whites, found multiple loci having GWAS-significant association with WBC counts. Data from more than 19,000 individuals were analyzed in the discovery stage, and 11,823 more in replication, finding that 10 regions significantly associated with total WBC counts and five with specific WBC subtypes spread across seven genomic loci. Only three of these associations were previously known.

The investigation identified an additional genetic region that significantly influences WBC counts: A variant in the chemokine ligand 2 (CXCL2), codes for a cytokine affecting polymorphonuclear leukocytes. This association has been recognized in Hispanic, white, and Japanese populations as well. The authors of the African-American study concluded that the new findings will contribute to our understanding of genetic factors underlying variation in WBC counts within and between populations and highlight the importance of common genetic variants in genomic regions encoding chemokine ligands and receptors to regulation of myelopoiesis and circulating leukocyte counts in human populations." The three studies were published online on June 30, 2011, in the Public Library of Science Genetics.

Related Links:
US National Institutes of Health






Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.